254 related articles for article (PubMed ID: 25859981)
1. Integrated multimodal imaging of dynamic bone-tumor alterations associated with metastatic prostate cancer.
Brisset JC; Hoff BA; Chenevert TL; Jacobson JA; Boes JL; Galbán S; Rehemtulla A; Johnson TD; Pienta KJ; Galbán CJ; Meyer CR; Schakel T; Nicolay K; Alva AS; Hussain M; Ross BD
PLoS One; 2015; 10(4):e0123877. PubMed ID: 25859981
[TBL] [Abstract][Full Text] [Related]
2. Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model.
Rozel S; Galbán CJ; Nicolay K; Lee KC; Sud S; Neeley C; Snyder LA; Chenevert TL; Rehemtulla A; Ross BD; Pienta KJ
J Cell Biochem; 2009 May; 107(1):58-64. PubMed ID: 19259948
[TBL] [Abstract][Full Text] [Related]
3. Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer.
Msaouel P; Nandikolla G; Pneumaticos SG; Koutsilieris M
Expert Opin Investig Drugs; 2013 Nov; 22(11):1385-400. PubMed ID: 24024652
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644: an aminobisphosphonate derivative.
Zhang S; Gera L; Mamouni K; Li X; Chen Z; Kucuk O; Wu D
Oncotarget; 2016 May; 7(19):27489-98. PubMed ID: 27050371
[TBL] [Abstract][Full Text] [Related]
5. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
[TBL] [Abstract][Full Text] [Related]
6. Predictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer.
Cook LM; Araujo A; Pow-Sang JM; Budzevich MM; Basanta D; Lynch CC
Sci Rep; 2016 Jul; 6():29384. PubMed ID: 27411810
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in bone-targeted therapies of metastatic prostate cancer.
Deng X; He G; Liu J; Luo F; Peng X; Tang S; Gao Z; Lin Q; Keller JM; Yang T; Keller ET
Cancer Treat Rev; 2014 Jul; 40(6):730-8. PubMed ID: 24767837
[TBL] [Abstract][Full Text] [Related]
8. An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone.
Lee KC; Sud S; Meyer CR; Moffat BA; Chenevert TL; Rehemtulla A; Pienta KJ; Ross BD
Cancer Res; 2007 Apr; 67(8):3524-8. PubMed ID: 17440058
[TBL] [Abstract][Full Text] [Related]
9. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
[TBL] [Abstract][Full Text] [Related]
10. Bone-targeting agents in prostate cancer.
Suzman DL; Boikos SA; Carducci MA
Cancer Metastasis Rev; 2014 Sep; 33(2-3):619-28. PubMed ID: 24398856
[TBL] [Abstract][Full Text] [Related]
11. Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer.
Parker SJ; Pond GR; Agarwal N; Alex A; Heilbrun ME; Sonpavde G
Clin Genitourin Cancer; 2017 Feb; 15(1):53-59. PubMed ID: 27338517
[TBL] [Abstract][Full Text] [Related]
12. Current trials using bone-targeting agents in prostate cancer.
Tu SM; Lin SH
Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
[TBL] [Abstract][Full Text] [Related]
13. Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity.
Nordstrand A; Bovinder Ylitalo E; Thysell E; Jernberg E; Crnalic S; Widmark A; Bergh A; Lerner UH; Wikström P
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670000
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance imaging for detection of prostate cancer metastatic to bone.
Turner JW; Hawes DR; Williams RD
J Urol; 1993 Jun; 149(6):1482-4. PubMed ID: 8501793
[TBL] [Abstract][Full Text] [Related]
15. Quality of life with advanced metastatic prostate cancer.
Resnick MJ; Penson DF
Urol Clin North Am; 2012 Nov; 39(4):505-15. PubMed ID: 23084527
[TBL] [Abstract][Full Text] [Related]
16. Targeting bone metastases in prostate cancer: improving clinical outcome.
Body JJ; Casimiro S; Costa L
Nat Rev Urol; 2015 Jun; 12(6):340-56. PubMed ID: 26119830
[TBL] [Abstract][Full Text] [Related]
17. Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies.
Saad F; Colombel M
Expert Rev Anticancer Ther; 2010 Dec; 10(12):1991-2002. PubMed ID: 21110764
[TBL] [Abstract][Full Text] [Related]
18. Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates.
Green JR
Acta Oncol; 2005; 44(3):282-92. PubMed ID: 16076701
[TBL] [Abstract][Full Text] [Related]
19. The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.
Morgan C; Lewis PD; Jones RM; Bertelli G; Thomas GA; Leonard RC
Acta Oncol; 2007; 46(5):669-77. PubMed ID: 17562444
[TBL] [Abstract][Full Text] [Related]
20. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma.
Mosavi F; Johansson S; Sandberg DT; Turesson I; Sörensen J; Ahlström H
AJR Am J Roentgenol; 2012 Nov; 199(5):1114-20. PubMed ID: 23096187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
